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Abstract  
Polyphosphate (polyP) binds to fibrin(ogen) and alters fibrin structure, generating a 
heterogeneous network composed of ‘knots’ interspersed by large pores.  Here we 
show platelet-derived polyP elicits similar structural changes in fibrin and examine the 
mechanism by which polyP alters fibrin structure. Polymerisation of fibrinogen with 
thrombin and CaCl2 was studied using spinning disk confocal (SDC) microscopy.  
PolyP delayed fibrin polymerisation generating shorter protofibrils emanating from a 
nucleus-type structure.  Consistent with this, cascade blue-polyP accumulated in fibrin 
‘knots’.    Protofibril formation was visualized by atomic force microscopy (AFM) ± 
polyP.  In the presence of polyP abundant monomers of longer length were visualized 
by AFM, suggesting that polyP binds to monomeric fibrin.  Shorter oligomers form in 
the presence of polyP, consistent with the stunted protofibrils visualized by SDC 
microscopy.  We examined whether these structural changes induced by polyP alter 
fibrin’s viscoelastic properties by rheometry.  PolyP reduced the stiffness (G’) and 
ability of the fibrin network to deform plastically G’’, but to different extents.   
Consequently, the relative plastic component (loss tangent (G’’/G’)) was 61% higher 
implying that networks containing polyP are less stiff and more plastic.  Local 
rheological measurements, performed using magnetic tweezers, indicate that the fibrin 
dense knots are stiffer and more plastic, reflecting the heterogeneity of the network.  
Our data show that polyP impedes fibrin polymerisation, stunting protofibril growth 
producing ‘knotted’ regions, which are rich in fibrin and polyP.  Consequently, the 
mechanical properties of the fibrin network are altered resulting in clots with overall 
reduced stiffness and increased ability to deform plastically.      
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Introduction 
Abnormal clot structure is linked to a number of thrombotic diseases (1-5).  The 
composition of the fibrin network determines the mechanical properties and its stability.  
Fibrinogen levels are directly associated with fibrin clot structure, with higher 
concentrations leading to an increase in the number and length of the fibres as well as 
enhancing fibre diameter.  In line with these observations elevated levels of plasma 
fibrinogen are a risk factor for cardiovascular disease (6).  Thrombin concentration has 
a profound impact on the architecture of a fibrin clot, (7) with high concentrations 
producing clots composed of thin compactly packed fibres. It is these dense clots that 
are linked to venous and arterial thromboembolic complications (2, 3, 5, 8-10). The 
resulting structure of a clot dictates the rate of fibrinolysis.  Individually, thin fibres are 
lysed quicker however, at the network level, clots composed of thick loosely woven 
fibres are lysed more rapidly (11).  Therefore, it is the composition of the fibrin network 
that influences clot resolution rather than individual fibre diameter.   
 
PolyP is a biomolecule composed of orthophosphate residues (Pi) linked by 
phosphoanhydride bonds.  PolyP of an average chain length of 60-100 mers is 
released from the dense granules of stimulated platelets (12, 13).  Activation of normal 
circulating levels of platelets is sufficient to generate concentrations of around 1-3 µM 
polyP in whole blood (12, 14).  However, in the milieu of a thrombus local polyP 
concentrations are likely to be several orders of magnitude higher due to the 
substantial accumulation of platelets.  PolyP is both pro-inflammatory and pro-
coagulant in vivo (13, 15) and modulates haemostasis at a number of points in the 
cascade (reviewed in (16)) including binding fibrin(ogen) and altering the structure of 
the resulting clot (17, 18).  Inhibition of polyP inhibits thrombin generation at arterial 
shear rates and fibrin generation at both venous and arterial shear rates (19) and polyP 
inhibitors have been recently proposed as novel antithrombotic agents (20, 21).  We 
have shown that fibrin networks produced in the presence of polyP are very 
heterogeneous with dense ‘knotted’ regions interspersed by pores (18).  A 
consequence of this altered structure is attenuation of tissue plasminogen activator 
(tPA) and plasminogen binding to fibrin thereby down-regulating tPA(16)-mediated 
fibrinolysis in the presence of polyP (18).  The regulatory role of polyP in haemostasis 
has been proposed to act to promote rapid resolution of injury upon activation of 
platelets by enhancing coagulation, whilst inhibiting fibrinolysis to allow repair (14).     
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Here we sought to determine the molecular mechanisms underlying the structural 
changes observed in fibrin clots formed in the presence of polyP of approximately the 
size range of that found in platelets (60-100 mer) (13).  We investigated changes in 
early fibrin polymerisation in the presence of polyP in real-time using spinning disk 
confocal (SDC) microscopy and at high resolution using atomic force microscopy.  
PolyP delayed fibrin polymerisation producing stunted protofibrils which moved with a 
reduced velocity.  Rheological measurements indicate that clots formed with polyP 
exhibit altered mechanical properties which may alter their ability to respond to shear 
stress in vivo. 
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Materials and Methods 
 
Materials 
Plasminogen free human fibrinogen (Fib 1) and Glu-plasminogen were purchased from 
Enzyme Research Laboratories (Swansea, UK).  Alexa-fluor 488 (AF488) conjugated 
fibrinogen from human plasma, Cascade Blue™ ethylenediamine, trisodium salt were 
from Molecular Probes (Leiden, The Netherlands) and 4.5 µm superparamagnetic 
beads (Dynabeads M-450 Epoxy) were from Life Technologies (Paisley, UK).  
Thrombin from human plasma (T1063) and polyphosphate (type 65; polyP) were 
purchased from Sigma-Aldrich (Dorset, UK).  Capillary tubes for magnetic tweezers 
were 0.5 mm in diameter and 5 cm in length (VitroCom; Mountain Lakes, NJ, USA).  1-
ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDAC), Slide-A-Lyzer dialysis 
cassettes G2 (2K MWCO 3ml) were purchased from Thermo Scientific (Rockford, IL, 
USA).  PolyP of an average chain length of 70 phosphate monomers, used for the 
cascade blue labelling, was a kind gift from Dr Thomas Staffel BK Giulini GmbH 
(Ludwigshafen, Germany).  Platelet-derived polyP was extracted from outdated 
apheresis platelets as described (22).  PolyP concentrations are expressed as 
monomer concentrations throughout (monomer formula NaPO3).  Where indicated, 
thrombin and fibrinogen concentrations were altered due to the specific requirements 
and constraints of the experimental procedures. Unless otherwise stated all reactions 
were carried out with human plasminogen-free fibrinogen (1.5 mg/ml) ± polyP (328 µM) 
with thrombin (0.25 U/ml) and calcium chloride (5 mM) in TBS (50 mM tris, 100 mM 
NaCl pH 7.4).   
 
Fibrin polymerisation measurements 
Changes in turbidity were monitored by taking measurements every 30 s at 340 nm for 
60 min at 37 ˚C using a BioTek ELX808 microplate plate reader.  SDC microscopy 
studies of fibrin polymerization were carried out as previously described (23) with the 
following modifications.  Fibrinogen (1.62 mg/ml, 7% as AF488-fibrinogen) was 
polymerized by the addition of thrombin (0.25 U/ml) and CaCl2 (5 mM) ± polyP.  
Polymerization reactions took place in Ibidi µ slides with a channel height of 400 µm.  
A stack of 30 images was acquired every 15 s for 45 min at 37 ˚C on a UltraVIEW Vox 
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3D live cell imaging system with a plan Apo VC x60/1.40 NA oil objective OFN 25 DIC 
N2 using Velocity software (Perkin Elmer, Waltham, MA, USA).  The velocity of the 
moving fibrin structures was calculated by measuring the distance travelled between 
subsequent images of 3 representative structures from each data set using Image J 
software (National Institutes of Health, Bethesda, US). 
 
Clot rheometry 
The viscoelastic properties of the overall fibrin network were measured on an AR G2 
Rheometer (TA Instruments; New Castle, DE, USA).   Measurements were taken 
during polymerization at 37˚C every 18 s for 80 min using a 40 mm parallel plate, gap 
of 220 mm, strain of 2 % and frequency of 5 rad/s.  The elastic modulus, G’, gives 
information about the energy stored during deformation translated into clot stiffness. 
The loss modulus, G’’, gives information about energy loss during deformation 
translated into the viscous component of the clot.  The loss tangent tanδ = G”/G’ was 
also calculated.   
 
In addition, an in-house built magnetic tweezers system was used to examine local 
microrheology in fibrin clots (24) by applying a magnetic force over a 4.5 µm 
superparamagnetic bead and measuring its displacement in the clot.  Clots, formed in 
the presence of superparamagnetic beads by addition of thrombin (0.25 U/ml) to 
fibrinogen (0.5 mg/mL) and CaCl2 (2.5 mM), ± polyP, were immediately transferred to 
a thin capillary tube and allowed to polymerize for 3 h.  An electromagnetic force (40 
pN) was applied using four electromagnets mounted on top of an inverted Olympus IX-
71 microscope (Olympus; Southend, UK) and connected to Kepco BOP 20-5M 
amplifiers (Kpeco Inc.; NY, USA) controlled using LabView software (National 
Instruments; Newbury, UK).  The position of the magnetic beads was tracked using 
CCD camera and measurements made, avoiding capillary walls where the clot was not 
densely packed.  Both elastic and viscous modulus of the fibrin clots were calculated 
from the time-dependent compliance in order to get frequency dependent moduli (25).  
The compliance was calculated as the ratio of the time-dependent shear strain (time-
dependent bead displacement) to the magnitude of the constant stress (force applied).  
In each clot the displacement of 10 particles (in different areas of the clot) were 
measured and each clot was studied in triplicate. The values presented in this paper 
were obtained at 0.1Hz.  
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Confocal Microscopy 
Cascade blue ethylenediamine (CB)-labelled polyP was prepared as described (26) 
and used to visualize its localization within the fibrin network.  Briefly, polyP (1 mg/ml) 
was incubated overnight at 37 ˚C with Cascade Blue ethylenediamine (1 mM), CaCl2 
(1 mM), EDAC (100 mM), and 2-(N-morpholino)ethanesulfonic acid (100 mM), pH 6.5.  
CB-polyP adducts were purified using Slide-A-Lyzer dialysis cassettes.  Clots were 
formed ± CB-polyP (328 µM) or platelet-derived polyP by polymerizing fibrinogen (0.87 
mg/ml, containing 9 % labelled with DL550-fibrinogen or AF488-fibrinogen) with 
thrombin (0.25 U/ml) and CaCl2 (5 mM).   
 
To visualize the localization of the superparamagnetic beads, clots were prepared as 
for the magnetic tweezers microrheology experiments in µ-slide VI0.4 (Ibidi; Martinsried, 
Germany) with the inclusion of AF488-fibrinogen (0.12 mg/ml).  Z-stack images (0.45 
or 0.5 µm slices) were taken on a Zeiss 710 laser scanning confocal microscope with 
a 63 x 1.40 oil immersion objective using Zeiss Zen 2012 software.  
 
Atomic force microscopy 
Protofibril formation was visualized by atomic force microscopy (AFM) by clotting 
fibrinogen (0.5 mg/ml) with thrombin (1 U/ml) and CaCl2 ± polyP.  Polymerization was 
allowed to proceed for 40 s before stopping the reaction by diluting in TBS and placing 
an aliquot on freshly cleaved MgCl2 mica pre-treated surface for imaging in air using a 
Bruker Multimode AFM and SNL-A Scanasyst probe. 
 
Statistical analysis 
Statistical analysis was performed in GraphPad Prism® 5.04 using one-way analysis 
of variance or two-way analysis of variance with Bonferroni post-hoc test or an 
unpaired Student’s t-test (2-tailed).  P < 0.05 was considered to be significant.  
Changes in rates of velocity (µm2/s) for fibrin polymerization measured by SDC 
microscopy were determined by best fit to a centered sixth order polynomial quadratic 
in GraphPad Prism® 5.04 and used to calculate fold differences in velocity. 
 
Results 
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PolyP accumulates in fibrin dense ‘knots’ 
The localization of CB-polyP within the clot was determined using confocal microscopy.  
CB-polyP accumulated in the knotted fibrin dense regions with a reduced fluorescent 
signal detected along the fibrin fibres that emanate from the ‘knots’ (Figure 1 A, 
supplementary video I).  A control clot formed in the absence of CB-polyP is shown for 
comparison (Figure 1B).  PolyP exists in various polymer lengths, with platelet-derived 
polyP ranging between 60 and 100 phosphate residues (12, 13). PolyP was extracted 
from human platelets and was included during fibrin polymerisation.  Inclusion of polyP 
isolated from human platelets during fibrin polymerisation mirrored the structural 
changes observed with synthetic polyP, with fibrin dense knots interspersed by large 
pores (Figure 1C).  
 
PolyP alters fibrin polymerisation 
Our previous observations showed that polyP reduced the maximum turbidity of polyP-
containing clots indicating an altered fibrin network, which we confirmed by confocal 
and scanning electron microscopy (18).  There was no detectable change in the lag 
time, however, change in turbidity is a crude measurement which does not allow for 
the real time study of the very early polymerisation events. Here we use SDC 
microscopy to visualise the dynamic process occurring during the first few minutes of 
polymerisation.  Initially, in control clots, small very fast moving structures were 
observed that gradually form thicker protofibrils before stabilizing into a fibrin network 
(Supplemental video II).  The presence of polyP resulted in smaller structures and 
delayed the time at which the first fibres were first observed by 21 s (P <0.05) (Figure 
2A-B).  Measurements of velocity were taken by tracking the movement of the same 
structure over time (Figure 2C).  Quantification of the velocity of the fibrin structures 
revealed a decrease in movement over time in both control and polyP clots (Figure 
2D).  This reduction in velocity over time is likely attributed to the increased size of the 
structures, due to elongation and lateral aggregation of fibres with time (23).  Clots 
containing polyP demonstrated a 2.4-fold (P <0.05) reduction in velocity compared to 
control clots (Figure 2C & D).  Stabilized clots (Figure 2A right hand panel) polymerised 
in the presence of polyP displayed the same heterogeneous knotted structures as 
previously observed (Figure 1; Supplementary video I).  
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Protofibrils are stunted during polymerisation with polyP 
SDC microscopy is capable of detecting protofibrils of a length of 0.5 µm and greater 
(23).   We further addressed the effects of polyP on early protofibril formation using 
AFM, which is a very high resolution technique that allows detection in the nanometer 
range.   Figure 3A shows representative images of monomers, dimers, trimers and 
tetramers.  The structure of the fibrin monomers including the αC regions were clearly 
visible at this high resolution (Figure 3A).   After 40 s of polymerisation in the presence 
of polyP more abundant fibrin monomers are observed (Figure 3B), indicative of slower 
fibrin polymerisation, consistent with the observations using SDC microscopy.  The 
monomeric fibrin structures (exhibiting clearly visible D-E-D regions) were 
approximately 8.8 nm longer in the presence of polyP compared to the control (58.4 ± 
1.4 nm vs. 49.6 ± 0.6 nm, P <0.0001) (Figure 3C).  This elongation likely indicates 
direct binding of polyP to fibrin monomers, consistent with our previous observations 
indicating binding to soluble fibrin (18).  Binding of polyP to fibrin monomers 
subsequently attenuated the size of the resulting dimers and trimers (Figure 3C).  
Larger fibrin structures are visible in the control clot compared to the polyP containing 
clot indicative of more advanced protofibril formation. These AFM observations 
suggest that the association of polyP and fibrin mechanically alters oligomer formation 
during early fibrin polymerisation steps.   
 
PolyP modulates the rheological properties of the clot  
We next addressed whether the structural changes in fibrin observed in the presence 
of polyP alter the rheological properties of the clot.  This was first measured in a 
rheometer during the polymerisation process.  Clots containing polyP were  4-fold less 
stiff than control clots (8.3 ± 0.8 Pa vs. 34.7 ± 6.9 Pa, P < 0.05) as indicated by their 
reduced storage modulus (G’), which is a measure of the stored energy and represents 
the elastic component (Figure 4A-B).   The loss modulus (G’’), which represents the 
energy dissipated as heat, was 2-fold higher in the control clots compared to those 
containing polyP (1.6 ± 0.1 vs. 0.7 ± 0.01, P < 0.01; Figure 4A-B).   As the change in 
the storage modulus was greater, the loss tangent (G’’/G’) for polyP containing clots 
was 57% (P < 0.05) higher in the presence of the polyP, indicating an increase in the 
relative plastic component (Figure 4C).  The lag time was prolonged in clots containing 
polyP, consistent with delayed polymerisation observed by SDC microscopy.  These 
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results imply that in the presence of polyP the overall fibrin network is less stiff and 
more likely to deform plastically.  
 
The microscale viscoelastic properties of fully polymerised crosslinked fibrin clots were 
further investigated using magnetic tweezers.  In this method clots are polymerised in 
the presence of supraparamagnetic beads which are trapped within the fibrin network.  
Due to the heterogeneous nature of polyP-containing clots, we analysed the location 
of the beads by confocal microscopy and found them to localize within the knotted fibrin 
regions (Figure 5A).   The tightly knotted fibrin areas in polyP-containing clots were 2-
fold stiffer than homogeneous control clots (G’ 0.50 ± 0.03 vs. 0.23 ± 0.01 Pa, P < 
0.0001) (Figure 5B).  Inclusion of polyP also increased the loss modulus 2-fold (G’’ 
0.24 ± 0.01 vs. 0.12 ± 0.01 Pa, P < 0.0001) and as a result there was no significant 
difference in the tan delta values.  This suggests that the fibrin dense knots, which 
accrue high concentrations of polyP, are stiffer in nature.  Taken together, these 
different viscoelastic measurements reflect the highly heterogeneous nature of the 
fibrin network formed in the presence of polyP.  
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Discussion 
Our observations (18) and others (17) have previously illustrated that polyP modulates 
the structural properties of a fibrin clot.  Here we demonstrate that these structural 
alterations in the fibrin network observed with synthetic polyP are mirrored with natural 
polyP that has been isolated from human platelets.  The heterogeneity of the fibrin 
network in the presence of polyP can be attributed to early events during clot 
development.  We visualize fibrin formation in real-time using SDC microscopy (23) 
and show that polyP significantly delays polymerisation of fibrin.  High resolution AFM 
microscopy reveals binding of polyP to fibrin monomers resulting in shorter protofibrils 
that exhibit reduced velocity during polymerisation.  These changes in polymerisation 
generate clots composed of fibrin dense aggregates, which contain a polyP-rich core, 
and are interspersed by large porous regions.  The extremely heterogeneous nature 
of polyP-containing clots is echoed in their viscoelastic properties, with distinct 
differences in the microscale and overall clot stiffness.     
 
PolyP binds to fibrinogen and soluble fibrin (18) and is incorporated into clots during 
polymerisation (17).  PolyP stored in platelet dense granules has a defined chain length 
of 60 – 10 phosphate residues (12, 13)  Here, we demonstrate that the structural 
changes observed with synthetic polyP are representative of those induced by natural 
form of polyP isolated from human platelets.  Using AFM we visualize the association 
of polyP with fibrin monomers, illustrated by the longer length of these microstructures.  
This binding results in accumulation of polyP within fibrin dense regions, suggesting it 
acts as a nucleus for fibrin formation.  In bacteria, polyP functions as a chaperone to 
stabilize cytoplasmic proteins by binding to unfolded proteins and preventing the 
formation of protein aggregates (27).  Precipitation of polyP into spherical 
nanoparticles in the presence of 5 mM CaCl2 has recently been described (28). These 
nanoparticles had more potent activity towards the contact system.  We have 
previously shown that polyP has the most pronounced effect on fibrinolysis at a CaCl2 
concentration of 2.5 – 5 mM (18) and in these studies have used 5 mM throughout.   
We also found that the polyP used in this study was visualised as a spherical form by 
AFM (data not shown), suggesting it functions as a polyP nanoparticle.  During fibrin 
polymerisation polyP may act as a surface that attracts fibrinogen, creating dense 
areas of fibrin.  This initial network forms the scaffold for deposition of subsequent 
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fibrinogen molecules (29, 30).  Therefore the localization of polyP within these early 
stages of polymerisation may act as a blueprint for the resulting fibrin network.   
 
The rate of polymerisation has a direct impact on the resulting fibrin network structure.  
During the lag phase there is rapid movement of fibrin structures with formation of the 
initial scaffold corresponding to the gel point (30).  As the turbidity increases the 
scaffold stabilizes allowing branch point formation and lateral growth of fibres (30).  In 
general, the turbidity of fibrin gels is proportional to the average cross-sectional area 
of the fibres (31).  However, in the presence of polyP, the resulting heterogeneous clot 
structure provides an example of a clot where the turbidity is not proportional to the 
average cross-sectional area of the fibres.  Inclusion of polyP delayed polymerisation 
observed by SDC microscopy producing stunted fibrin structures with reduced mobility.  
Consistent with the SDC microscopy, AFM revealed a reduction in oligomer length, 
which is directly linked to the rate of polymerisation (32).      
 
The viscoelastic properties of the fibrin network are closely related to its mechanical 
stability.  Here the rheological properties of polyP-containing clots, quantified during 
polymerisation, demonstrated a reduction in both the storage and loss moduli.  The 
decrease in storage modulus was greater, resulting in an increased loss tangent 
indicating that polyP-containing clots are less stiff with an increased plastic component.  
These characteristics may seem conflicting; however, they likely reflect the 
heterogeneous nature of these clots, with the porous loose regions accounting for the 
reduction in stiffness.  We also assessed the local rheological properties of fully 
polymerised and cross-linked clots using magnetic tweezers.  In these measurements 
the supraparamagnetic beads were directly incorporated into the knotted regions of 
fibrin that are rich in polyP.  Using this technique we found an increase in the storage 
modulus with polyP, indicative of an increased stiffness.  These observations are in 
agreement with thromboelastography measurements performed on fully polymerised 
clots (17).  These differences, while conflicting reflect the ongoing changes that occur 
in a fibrin network when it transitions from the polymerisation stage to a fully formed 
scaffold (30).  The addition, removal or inhibition of factor XIII does not alter the effects 
of polyP (17, 18).  Therefore, the changes in the fibrin network are not explained by 
differences in crosslinking.   Changes in the viscoelastic properties of a clot will affect 
how it responds to forces such as blood flow.  Clots with a reduced storage modulus 
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are more likely to deform irreversibly and as the plastic component of these clots 
increases, induced deformation is likely to be permanent (33).   The stiffness of the clot 
remains constant over a range of different rates of stress (33) therefore within platelet-
rich areas of a clot, with high local concentrations of polyP, this would reduce the 
overall stiffness and modulate how the clot reacts to different stresses such as clot 
retraction and shear rate.  
 
The αC region of fibrinogen compromises the terminal two thirds of the carboxyl 
terminal of the Aα chain.  During conversion of fibrinogen to fibrin the αC regions 
dissociate from the central E domain allowing intermolecular interactions and 
enhancing lateral aggregation (34-36).  Interestingly, clots formed with fibrinogen 
truncated at Aα residue 251, show a reduction in stiffness and more plastic deformation 
(37).    There is a net positive charge on the αC regions which could favour interaction 
with negatively charged polymers such as polyP (38).  The αC regions are the most 
unfolded part of fibrin(ogen) and in view of the fact that polyP acts as chaperone to 
unfolded proteins in bacteria (27), it is conceivable that it interacts with polyP in a 
similar manner.   PolyP increased the length of fibrin monomers which could be due to 
the αC region extending beyond the D-region, resulting in a longer structure due to the 
association of polyP.  During formation of larger structures the αC region has to extend 
laterally rather than longitudinally to allow D-D interactions which could be enhanced 
by polyP, perhaps resulting in the observed shortened oligomers.  It is interesting to 
speculate that by binding to this region polyP alters the structural and rheological 
properties of the fibrin network, but further work is necessary to characterize the exact 
binding site of polyP on fibrinogen. 
 
Detection of abnormal changes to clot structure has the potential as a biomarker of 
thrombotic disease.   Recently, clot fractal dimension (df) has been proposed as a test 
for abnormal clot microstructure and predictor of recurrent VTE (39).   Changes in the 
fibrin network translate into alterations in the susceptibility to fibrinolysis.  The resulting 
heterogeneous network with polyP has a reduced permeability and the rate of 
fibrinolysis by tPA is reduced due to impaired binding of tPA and plasminogen to 
partially degraded fibrin (18).  Interestingly, the binding sites for tPA and plasminogen 
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on fibrin are also concentrated in the αC regions suggesting a possible mechanism by 
which polyP attenuates binding of these proteins.   
 
In conclusion, we have shown that platelet-derived polyP elicits the same structural 
changes in fibrin as previously described for synthetic polyP.  We found that polyP 
modulated the early polymerisation events of fibrin formation by binding directly to 
fibrin(ogen), thereby altering oligomer formation, producing stunted fibrin structures 
that move with reduced velocity.  PolyP acts as a nucleus for dense accumulations of 
fibrin which are interspersed by a looser porous network. The heterogeneous nature 
of the network is conveyed in its viscoelastic properties producing a clot with reduced 
stiffness and increased ability to deform plastically, but with local micro-pockets of 
increased stiffness in areas where polyP is concentrated on fibrin.   
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Figure legends 
Figure 1 – Visualisation of polyP with fibrin network.  Clots were formed ± CB-
polyP or platelet-derived polyP (328 µM) by polymerising fibrinogen (0.87 mg/ml, with 
9 % labelled with DL550-fibrinogen or AF488-fibrinogen) with thrombin (0.25 U/ml) and 
CaCl2 (5 mM).  Shown is a render of Z-stack representative image (A) polyP-containing 
clot with fibrinogen (green, top right panel) and polyP (blue, bottom right panel) and 
the merged image (left panel) Arrows indicate the presence of polyP in fibrin dense 
regions. (B) control clot formed in the absence of polyP.  (C) clot containing platelet-
derived polyP (left) and control clot (right) for comparison. Images were collected using 
a LSM 710 confocal microscope.  Representative image from n = 3, scale bar = 10 µm. 
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Figure 2 – PolyP alters fibrin polymerisation.  Fibrinogen (1.62 mg/ml, 7% as 
AF488-fibrinogen) was polymerised by the addition of thrombin (0.25 U/ml) and CaCl2 
(5 mM) ± polyP (328 µM) and monitored by SDC microscopy.   A stack of 30 images 
was acquired every 15 s for 45 min at 37 ˚C.  (A) Time course images showing delayed 
polymerisation in the presence of polyP and the stabilized clots at 45 min.  (B) The 
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time at which fibres were first visualized.  (C) Overlaid images from representative 
structures ± polyP at 3 different time points. Arrows indicated direction of movement, 
scale bar = 10 µm. (D) The velocity of the fibrin structures was calculated by measuring 
the distance travelled between subsequent images of 3 representative structures from 
each data set using Image J software. Data are expressed as mean ± SEM, n = 4. 
 
 
 
Figure 3 – Protofibril formation visualised using AFM.   Fibrinogen (0.5 mg/ml) was 
polymerised for 40 s by addition of thrombin (1 U/ml) and CaCl2 (5 mM) ± polyP and 
the reaction stopped by diluting then imaged using Bruker Multimode AFM and SNL-A 
Scanasyst probe (air).  (A) Representative images of a monomer, dimer, trimer and 
tetramer structure. Clearly distinguishable are the central E regions, D regions and in 
the monomers the αC regions (B) Representative images from control and polyP 
containing reactions.  Images show a 1 µm2 area.  (C) Calculation of structure length 
using Nanoscope analysis software.  Twelve fibrin structures representing monomers, 
dimers, trimers and tetramers were measured from 3 separate images. 
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Figure 4 - Rheological properties of the fibrin network.   Measurements were taken 
during polymerisation of fibrinogen (1.5 mg/ml) ± polyP (328 µM) by the addition of 
thrombin (0.25 U/ml) and CaCl2 (5 mM) on a rheometer at 37˚C every 18 s for 80 min.   
Shown are (A) plots and (B) histograms of the average storage (G’) and loss (G’’) 
moduli and (C) the loss tangent (𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 = 𝐺𝐺′′ 𝐺𝐺′⁄ ).  * P <0.05, ** P <0.01 compared with 
control clots.  Data are expressed as mean ± SEM, n = 3. 
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Figure 5 - Magnetic tweezers measurements of the local rheological properties.  
Fibrin clots were formed by addition of thrombin (0.25 U/ml) to fibrinogen (0.5 mg/mL) 
and CaCl2 (2.5 mM), ± polyP (328 µM) in the presence of superparamagnetic beads.  
(A)  Localization of the superparamagnetic beads was visualized within the clots with 
the inclusion of AF488-fibrinogen (19% of total fibrinogen) on a Zeiss 710 laser 
scanning confocal microscope.  DIC = differential interference contrast.  Arrows 
indicate supraparamagnetic beads, scale bar = 10 µm. (B) An electromagnetic force 
(40 pN) was applied and the position of the magnetic beads tracked using CCD 
camera.   Displacement of 10 particles per clot were measured and each clot was 
studied in triplicate. The values presented were obtained at frequency 0.1Hz. **** P 
<0.0001, compared with control clots.  Data are expressed as mean ± SEM, n = 3.   
 
What is known on this topic? What this paper adds 
• PolyP binds to fibrin(ogen). 
• PolyP alters the fibrin network 
structure forming clots with fibrin 
• PolyP delays fibrin polymerisation 
and stunts protofibril growth. 
• PolyP is localized in the dense fibrin 
knots. 
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aggregates interspersed by large 
pores. 
 
• Overall clots containing polyP are 
less stiff and more likely to deform 
plastically. 
 
 
